{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-23-000136","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.141537+00:00","generated_at":"2026-06-08T18:59:25.123911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance","bullets":["Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).","Net loss decreased 50% to $19M; Adjusted EBITDA turned positive at $3M vs -$12M YoY.","Raised FY23 revenue guidance to $585-592M (15-16% growth); Adj. EBITDA loss guidance improved to $4M-$1M loss.","Cash and marketable securities $402M at quarter end.","Adjusted Gross Profit Margin 44.2%, excluding amortization of acquired Inivata developed technology intangibles."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-23-000136","json":"https://secwatch.observer/filing/0001077183-23-000136.json","markdown":"https://secwatch.observer/filing/0001077183-23-000136.md","text":"https://secwatch.observer/filing/0001077183-23-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/neo-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:59:25.123911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84b163317de7cda565f593ba4f743c67748d6829","claim":"NEOGENOMICS INC reported its third fiscal quarter of 2023 results: revenue $152 million, net income $19 million. Guidance raised.","evidence_excerpt":"as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its third-quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its third fiscal quarter of 2023"},{"label":"Revenue","value":"$152 million"},{"label":"Net income","value":"$19 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}